Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F22%3A00013355" target="_blank" >RIV/00023736:_____/22:00013355 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1038/s41409-022-01577-x" target="_blank" >https://doi.org/10.1038/s41409-022-01577-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41409-022-01577-x" target="_blank" >10.1038/s41409-022-01577-x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT

Popis výsledku v původním jazyce

Whether to choose haploidentical (Haplo) or one-antigen mismatched unrelated donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PTCy) remains an unanswered question. We compared PTCy- Haplo-HCT to PTCy-1Ag-MMUD-HCT for acute myeloid leukemia (AML) in complete remission (three groups: 1Ag-MMUD using peripheral blood (1Ag-MMUD-PB, n = 155). Haplo using bone marrow (Haplo-BM, n = 647) or peripheral blood (Haplo-PB, n = 949)). Haplo-BM and Haplo-PB had a higher non-relapse mortality (NRM) compared to 1Ag-MMUD-PB (HR 2.28, 95pct CI 1.23-4.24, p less than 0.01, HR 2.65, 95pct CI 1.46-4.81, p more than 0.01, respectively). Haplo groups experienced a lower leukemia-free survival (LFS) compared to 1Ag-MMUD-PB (Haplo-BM: HR 1.51, 95pct CI 1.06-2.14, p = 0.02, Haplo-PB: 1.47, 95pct CI 1.05-2.05, p = 0.02), overall survival (OS) was also lower in Haplo-HCT (Haplo-BM: HR 1.50, 95pct CI 1.02-2.21, p = 0.04, Haplo-PB: HR 1.51, 95pct CI 1.05-2.19, p = 0.03). No differences were observed for graft-versus-host/relapse-free survival (GRFS) and relapse incidence (RI). Haplo-BM was associated with a lower risk of grade III-IV acute graft-versus-host disease (GVHD) (HR 0.44, 95pct CI 0.24-0.81, p less than 0.01), while no statistical differences were observed between groups for grade II-IV aGVHD and for cGVHD. Use of PTCy in 1Ag-MMUD-HCT is a valid alternative to consider when using alternative donors. Larger analysis of 1Ag-MMUD versus haplo-HCT are warranted.

Název v anglickém jazyce

Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT

Popis výsledku anglicky

Whether to choose haploidentical (Haplo) or one-antigen mismatched unrelated donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PTCy) remains an unanswered question. We compared PTCy- Haplo-HCT to PTCy-1Ag-MMUD-HCT for acute myeloid leukemia (AML) in complete remission (three groups: 1Ag-MMUD using peripheral blood (1Ag-MMUD-PB, n = 155). Haplo using bone marrow (Haplo-BM, n = 647) or peripheral blood (Haplo-PB, n = 949)). Haplo-BM and Haplo-PB had a higher non-relapse mortality (NRM) compared to 1Ag-MMUD-PB (HR 2.28, 95pct CI 1.23-4.24, p less than 0.01, HR 2.65, 95pct CI 1.46-4.81, p more than 0.01, respectively). Haplo groups experienced a lower leukemia-free survival (LFS) compared to 1Ag-MMUD-PB (Haplo-BM: HR 1.51, 95pct CI 1.06-2.14, p = 0.02, Haplo-PB: 1.47, 95pct CI 1.05-2.05, p = 0.02), overall survival (OS) was also lower in Haplo-HCT (Haplo-BM: HR 1.50, 95pct CI 1.02-2.21, p = 0.04, Haplo-PB: HR 1.51, 95pct CI 1.05-2.19, p = 0.03). No differences were observed for graft-versus-host/relapse-free survival (GRFS) and relapse incidence (RI). Haplo-BM was associated with a lower risk of grade III-IV acute graft-versus-host disease (GVHD) (HR 0.44, 95pct CI 0.24-0.81, p less than 0.01), while no statistical differences were observed between groups for grade II-IV aGVHD and for cGVHD. Use of PTCy in 1Ag-MMUD-HCT is a valid alternative to consider when using alternative donors. Larger analysis of 1Ag-MMUD versus haplo-HCT are warranted.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bone marrow transplantation

ISSN

0268-3369

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

562-571

Kód UT WoS článku

000668928500144

EID výsledku v databázi Scopus

2-s2.0-85123489227